We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Trends in drug-coated device use for peripheral artery disease: Insights from the Vascular Quality Initiative (VQI).
- Authors
Pichert, Matthew D; Smolderen, Kim G; Castro-Dominguez, Yulanka; Jelani, Qurat-Ul-Ain; Nagpal, Sameer; Provance, Jeremy B; Huang, Jiaming; Malik, Ali O; Secemsky, Eric A; Derbas, Laith A; Mena-Hurtado, Carlos I
- Abstract
Going forward, contemporary surveillance data for PAD devices are, however, very much needed as it can help tailor the most favorable benefit-risk ratio of drug-coated devices to patient-level factors and angiographic-level factors. Keywords: drug coated balloon; peripheral artery disease (PAD); utilization EN drug coated balloon peripheral artery disease (PAD) utilization 73 74 2 02/04/22 20220201 NES 220201 Paclitaxel-coated devices were frequently used for the treatment of femoropopliteal peripheral artery disease (PAD) after the first FDA-approved device came to market at the end of 2012.[1] Since then, a series of paclitaxel drug-eluting stents (DES) and drug-coated balloons (DCB) have been developed and are currently approved for the treatment of femoropopliteal PAD.[1],[2] Paclitaxel, a chemotherapeutic agent, prevents neointimal hyperplasia resulting in improved patency and freedom from reintervention when compared with bare metal stents (BMS) and plain balloon angioplasty (POBA).[2],[3] Despite superior efficacy outcomes, recent events have taken place that may have impacted paclitaxel devices' widespread use.
- Subjects
PERIPHERAL vascular diseases; DRUG-eluting stents; POPLITEAL artery; TRANSLUMINAL angioplasty
- Publication
Vascular Medicine, 2022, Vol 27, Issue 1, p73
- ISSN
1358-863X
- Publication type
Letter
- DOI
10.1177/1358863X211043567